Drug developer Noxopharm is following up on indications that an experimental anti-cancer drug may be effective against the Covid-19 coronavirus. Melbourne’s Hudson Institute of Medical Research has identified anti-inflammatory properties of the experimental drug idronoxil, the active ingredient in the company’s anti-cancer drug candidate Veyonda. Pre-clinical models indicate the drug has the ability to treat…
Pharmaceutical developer Noxopharm has been awarded patent protection for its Veyonda treatment for late-stage cancers. The patent, one of a number of families of patents the company is seeking in major drug markets, is for a suppository formulation including the drug idronoxil. Idronoxil is an inhibitor of sphingosine-1-phosphate (S1P) – a messenger in cells that…
Metastatic cancer treatment biotech Noxopharm (ASX NOX) has successfully listed its Nyrada Inc spin off on the Australian Stock Exchange. Noxopharm, which is focusing on commercialising its Veyonda treatment for late-stage cancers, listed Nyrada to develop non-oncology drug prospects developed by the group. Nyrada is listed as a foreign company on the ASX through the…
Sydney anti-cancer treatment company Noxopharm (ASX: NOX) has reported anti-cancer effects of its Veyonda treatment in a small group of patients suffering advanced prostate cancer. The 14 patients’ cancers were metastatic and they had exhausted all treatment options when given Veyonda in association with low-dosage radiation in a single lesion. After six months, cancer progression…
CNC Design prints innovative lounge chair in two hours Additive manufacturing technology company CNC Design has demonstrated that 3D printing can print large items of furniture in a matter of hours, reducing production time and costs. The company displayed an innovative chair (pictured) at AMW 2023 exhibition at the RMIT University stand utilising a material…
UPS facility speeds safe dispatch of healthcare products UPS has announced the opening of a new cutting-edge healthcare facility that provides a boost to businesses shipping time-sensitive, temperature-sensitive, and patient-critical healthcare products. The 13,400 square-metre Horsley Park, Sydney facility offers product storage at temperatures as low as -20°C, near real-time monitoring, motion-activated LED lighting, and…
Remote control for space incubator applications close on Friday. Applications close on Friday for a national program launched last month to incubate innovative Australian SMEs and “scale-ups” into the global space industry. The Robotics, Automation & Remote Asset Control For Space And Earth Incubator is aimed at companies keen to scale, that have solutions with…
Boral hit by east coast floods Building products group Boral has seen its earnings hit adversely by lower sales following the recent floods in New South Eales and Queensland. The company now expects operating profit (EBIT) to fall to between $145 million and $155 million for FY22. CEO Zlatko Todorcevski said the impact to earnings…
Universal Biosensors executes US distribution deal Electrochemical test developer Universal Biosensors has signed another distribution deal in the United States for the company’s Sentia wine testing platform device. Vinmetrica (USA) will be non-exclusive distributor for a three year term for Sentia, which tests wine for sulphur dioxide, glucose, malic acid and other components of wine.…
Archer progresses biochip design Archer Materials has established chip testing and measurement operations (pictured) to support its development of a graphene-based biochip for point-of-care medical diagnostics. The capability has been established at a cleanroom at the University of Sydney’s semiconductor research and prototype foundry. The establishment of the facility allows Archer to progress to the…
